Neoadjuvant chemotherapy with pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel achieved a pathological complete response rate of 18.75% in locally advanced breast cancer.
Does neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel improve pathological complete response in locally advanced breast cancer?
Neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel achieved an 18.75% pathological complete response rate with no significant cardiotoxicity in locally advanced breast cancer.
p-value: p=<0.001
Abstract Anthracyclines have a profound effect on breast cancer. However, at higher dosages, there are many toxic side effects associated with their use; these include bone marrow suppression, alopecia, gastrointestinal reactions and cardiotoxicity. Pegylated liposomal doxorubicin (PEG-LG) has been demonstrated to achieve equivalent efficacy to conventional doxorubicin, with significantly lower cardiotoxicity. We conducted an open-label, multicenter, single-armed clinical trial useing an NAC regimen based on four cycles of PEG-LD 40 mg/m 2 plus cyclophosphamide (CPM) 600 mg/m 2 on day 1 of a 21 day schedule, followed by four cycles of docetaxel (DTX) 85 mg/m 2 on day 1 of a 21 day schedule. The primary endpoint analysed was the pathological complete response rate (pCR) in the breast, while treatment toxicities and safety were also assessed. The results showed that the breast pCR rate was 18.75% (95% CI 11.5–26.0%). Among the different molecular cancer types, the triple negative breast cancer patients had the highest pCR, at 43.75%. No significant decrease in left ventricular ejection fraction was observed. Our data tends to draw the conclusion that this regimen is a viable option for the neoadjuvant treatment of patients with LABC, especially in the triple-negative subtype and patients with heart abnormalities. We believe the efficacy and the safety of this regimen is likely to be the same based on published data from other studies but that this cannot be certain without a randomized trial.
Li et al. (Mon,) conducted a other in Locally advanced breast cancer (n=112). Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel was evaluated on Pathological complete response (pCR) rate in the breast (95% CI 11.5-26.0%, p=<0.001). Neoadjuvant chemotherapy with pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel achieved a pathological complete response rate of 18.75% in locally advanced breast cancer.